Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology
JCO Precision Oncology · 2024
DOI: 10.1200/po.23.00713 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Carolina Sgarioni Camargo Vince und 28 weiteren Autor:innen. Beteiligte Einrichtung: Childhood Cancer Treatment Institute (ITACI), São Paulo Medical School, University of São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Pyrazoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Our study aimed to explore real-world treatment scenarios for children and adolescents with neurotrophic tropomyosin receptor kinase (NTRK)–fused tumors, emphasizing access, responses, side effects, and outcomes. PATIENTS AND METHODS Pooled clinical data from 17 pediatric cases (11 soft-tissue sarcomas, five brain tumors, and one neuroblastoma) treated with larotrectinib and radiologic images for 14 patients were centrally reviewed. Testing for gene fusions was prompted by poor response to treatment, tumor progression, or aggressiveness. RESULTS Six different NTRK fusion subtypes were detected, and various payment sources for testing and medication were reported. Radiologic review revealed objective tumor responses (OR) in 11 of 14 patients: Complete responses: two; partial responses: nine; and stable disease: three cases. Grades 1 or 2 Common Terminology Criteria for Adverse Events adverse effects were reported in five patients. Regarding the entire cohort's clinical information, 15 of 17 patients remain alive (median observation time: 25 months): four with no evidence of disease and 11 alive with disease (10 without progression). One patient developed resistance to the NTRK inhibitor and died from disease progression while another patient died due to an unrelated cause. CONCLUSION This real-world study confirms favorable agnostic tumor OR rates to larotrectinib in children with NTRK-fused tumors. Better coordination to facilitate access to medication remains a challenge, particularly in middle-income countries like Brazil.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Childhood Cancer Treatment Institute (ITACI), São Paulo Medical School, University of São Paulo, São Paulo, Brazil.
- Hospital Israelita Albert Einstein, São Paulo, Brazil.
- Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
- Departament of Pediatric Oncology, Barretos Cancer Hospital, Barretos, Brazil.
- Department of Pediatrics, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
- Hospital Pequeno Príncipe, Curitiba, Brazil.
ORCID-Profile: Maria Sol Brassesco, Lauro Jose Gregianin, Edna Kakitani Carbone, Adham do Amaral E Castro, Carla Donato Macedo, Gildene Alves da Costa, Luciana Nunes Silva, Sima Esther Ferman, Vicente Odone-Filho, Marcelo Milone Silva, Rui Manuel Reis, Elvis Terci Valera
Zitieren
APA
Vince, C. S. C., Brassesco, M. S., Mançano, B. M., Gregianin, L. J., Carbone, E. K., do Amaral E Castro, A., Dwan, V. S. Y., Menezes da Silva, R. Z., Mariano, C. S., da Mata, J. F., Silva, M. O., Caran, E. M. M., Macedo, C. D., Alves da Costa, G., Esteves, T. C., Silva, L. N., Ferman, S. E., Martins, F. D., Cristófani, L. M., …, & Brazilian Committee of Precision Medicine in Pediatric Oncology (BC-PMPO)—the Brazilian Society of Pediatric Oncology (SOBOPE) (2024). Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology. JCO Precision Oncology. https://doi.org/10.1200/po.23.00713
Vancouver
Vince CSC, Brassesco MS, Mançano BM, Gregianin LJ, Carbone EK, do Amaral E Castro A, et al. Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology. JCO Precision Oncology. 2024. doi:10.1200/po.23.00713
BibTeX
@article{Vince2024,
author = {Vince, Carolina Sgarioni Camargo and Brassesco, Maria Sol and Mançano, Bruna Minniti and Gregianin, Lauro Jose and Carbone, Edna Kakitani and do Amaral E Castro, Adham and Dwan, Viviane Sayuri Yamachira and Menezes da Silva, Roberta Zeppini and Mariano, Cassia Silvestre and da Mata, Juliana França and Silva, Marcelo Oliveira and Caran, Eliana Maria Monteiro and Macedo, Carla Donato and Alves da Costa, Gildene and Esteves, Tereza Cristina and Silva, Luciana Nunes and Ferman, Sima Esther and Martins, Flavia Delgado and Cristófani, Lilian Maria and Odone-Filho, Vicente and Silva, Marcelo Milone and Reis, Rui Manuel and Pianovski, Mara Albonei Dudeque and Campregher, Paulo Vidal and Kunii, Mayara Satsuki and de Sá Rodrigues, Karla Emilia and Carvalho Filho, Neviçolino Pereira and Valera, Elvis Terci and Brazilian Committee of Precision Medicine in Pediatric Oncology (BC-PMPO)—the Brazilian Society of Pediatric Oncology (SOBOPE), Brazilian Committee of Precision Medicine in Pediatric Oncology (BC-PMPO)—the Brazilian Society of Pediatric Oncology (SOBOPE)},
title = {Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.23.00713}
}
EUVIMED